Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)
- Conditions
- Liver Cancer
- Interventions
- Biological: oblimersen sodium
- Registration Number
- NCT00047229
- Lead Sponsor
- University Health Network, Toronto
- Brief Summary
RATIONALE: Drugs used in chemotherapy such as doxorubicin use different ways to stop tumor cells from dividing so they stop growing or die. Oblimersen may increase the effectiveness of doxorubicin by making tumor cells more sensitive to the drug.
PURPOSE: Phase II trial to study the effectiveness of combining oblimersen with doxorubicin in treating patients who have locally advanced, recurrent, or metastatic hepatocellular carcinoma (liver cancer).
- Detailed Description
OBJECTIVES:
* Determine the maximum tolerated dose of oblimersen and doxorubicin in patients with advanced hepatocellular carcinoma or other incurable solid tumor (closed to accrual as of 11/7/03). (Phase I completed as of 1/16/04.)
* Determine the efficacy of this regimen, in terms of objective response rate, in these patients.
* Determine the toxicity of this regimen in these patients.
* Determine the time to progression, response duration, progression-free survival, median survival, and overall survival rates in patients treated with this regimen.
OUTLINE: This is a dose-escalation, multicenter study. (Phase I completed as of 1/16/04.)
Patients receive oblimersen IV continuously on days 1-7 and doxorubicin IV over 5 minutes on day 5. Treatment repeats every 4 weeks for up to 10 courses in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of oblimersen and doxorubicin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients\*, including 6 patients with hepatocellular carcinoma (HCC), are treated at the recommended phase II dose. (Phase I completed as of 1/16/04.)
NOTE: \*Other solid tumors closed to accrual as of 11/7/03; only accruing HCC patients
PROJECTED ACCRUAL: A total of 12-18 patients will be accrued for the phase I portion of this study within 6 months (phase I completed as of 1/16/04). A total of 30 patients will be accrued for the phase II portion of this study within 10-15 months.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 27
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description G3139 in combination with Doxorubicin oblimersen sodium - G3139 in combination with Doxorubicin doxorubicin hydrochloride -
- Primary Outcome Measures
Name Time Method Rate of objective response (complete and partial) Up to 280 days Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Objective Response (OR) = CR + PR. Objective response rate of \>= 30% is considered active, and \<10% is considered inactive.
- Secondary Outcome Measures
Name Time Method Median survival rate Up to 280 days Progression-free survival rate Up to 280 days Overall survival rate Up to 280 days Safety and tolerability Up to 280 days Stable disease rate Up to 280 days Duration of response Up to 280 days
Trial Locations
- Locations (3)
British Columbia Cancer Agency - Vancouver Cancer Centre
🇨🇦Vancouver, British Columbia, Canada
London Regional Cancer Program at London Health Sciences Centre
🇨🇦London, Ontario, Canada
Princess Margaret Hospital
🇨🇦Toronto, Ontario, Canada